Ultragenyx Pharmaceutical
RARE
164 hedge funds and large institutions have $2.16B invested in Ultragenyx Pharmaceutical in 2018 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 65 increasing their positions, 51 reducing their positions, and 35 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 51
0.96% more ownership
Funds ownership: 99.15% → 100.11% (+0.96%)
7% less funds holding
Funds holding: 176 → 164 (-12)
23% less call options, than puts
Call options by funds: $1.87M | Put options by funds: $2.44M
31% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 35
43% less capital invested
Capital invested by funds: $3.8B → $2.16B (-$1.64B)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$39.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$18.5M |
| 3 |
D.E. Shaw & Co
New York
|
+$17.3M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$17M |
| 5 |
Capital International Investors
Los Angeles,
California
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$21.1M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$20.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$20.8M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$19.4M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
-$17.3M |
RARE Hedge Fund Activity: Q4 2018 in Review
164 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2018, worth a combined $2.16B — down 43% from $3.8B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of RARE and 24 opened new positions — a net loss of 11 holders — while 51 trimmed existing stakes and 65 added.
The largest buyer was Wellington Management Group, adding an estimated $39.4M. The largest seller was Ameriprise, cutting an estimated $21.1M.
- 164 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2018, down from 176 in Q3 2018.
- Funds reported $2.16B of Ultragenyx Pharmaceutical stock for Q4 2018, down 43% quarter-over-quarter.
- 24 funds opened new Ultragenyx Pharmaceutical positions in Q4 2018 and 35 closed out, a net change of -11 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q4 2018 was Wellington Management Group, an estimated $39.4M added.
- The largest Ultragenyx Pharmaceutical seller in Q4 2018 was Ameriprise, an estimated $21.1M sold.
Based on aggregated 13F filings for Q4 2018.